Joint Letter of Support for Swift Action on the MEDS Act
Dear Chairman Alexander and Ranking Member Murray,
As the United States takes steps in response to the outbreak of COVID-19,...
Learn MoreGroup Comment Letter to FDA on Clinical Immunogenicity Considerations from Biosimilar and Interchangeable Insulin Products
Dear Commissioner Hahn,
The undersigned groups share the Food and Drug Administration’s (FDA) deep commitment to the development...
Learn MoreComments of the Healthcare Supply Chain Association (HSCA) on FDA Request for Comments on Ethylene Oxide Sterilization of Medical Devices
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments to the U.S. Food...
Learn MoreHSCA Submits Comments to ANSI on Healthcare Supply Chain Data Standards to Help Improve Accuracy, Efficiency, and Patient Safety
Washington, DC (November 26, 2019) – The Healthcare Supply Chain Association (HSCA) Committee for Healthcare eStandards (CHeS)...
Learn MoreJoint Letter of Support for the MEDS Act
Dear Senator Collins and Senator Smith,
The undersigned organizations are writing in support of S.2723 – The Mitigating...
Learn MoreHSCA Applauds Senators Collins and Smith for Bipartisan Legislation to Prevent and Mitigate Drug Shortages
Washington, DC (October 30, 2019) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released...
Learn MoreHSCA Statement on FDA Drug Shortages Task Force Report
Washington, DC (October 29, 2019) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released...
Learn MoreComments of the Healthcare Supply Chain Association (HSCA) on Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments on the U.S. Drug...
Learn More